Kai G. Kahl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kai G. Kahl has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Beate M. Stoeckelhuber
3 shared publicationsFritz Hohagen
3 shared publicationsHans-Björn Gehl
3 shared publicationsLeif Dibbelt
3 shared publicationsSebastian Rudolf
3 shared publicationsUlrich Schweiger
3 shared publications
Latest Publications
- 20 October 2005
- Vol. 147 (42) , 32-4, 36
[The metabolic syndrome and mental illness: relevance, risk factors and practical consequences].
The prevalence of the metabolic syndrome and its sequelae (cardiovascular diseases and diabetes mellitus) is elevated in patients with depression and schizophrenic disorders in comparison with mentally healthy persons. A variety of factors have been proposed to explain this association. These include overlapping pathophysiological mechanisms, an unhealthy lifestyle (poor dietary choices, smoking, lack of exercise), genetic factors and a lack of compliance with therapeutic programs. In addition to this, attention is increasing being focused on the metabolic side effects of (atypical) neuroleptics. Cases of acute ketoacidosis may also be associated with the use of these substances. Since none of the neuroleptics currently commercially available can be guaranteed to be free of metabolic side effects, strict monitoring of depressive or schizophrenic patients receiving such treatment is mandatory.
- 20 October 2005
- Vol. 147 (42) , 32-4, 36
[The metabolic syndrome and mental illness: relevance, risk factors and practical consequences].
The prevalence of the metabolic syndrome and its sequelae (cardiovascular diseases and diabetes mellitus) is elevated in patients with depression and schizophrenic disorders in comparison with mentally healthy persons. A variety of factors have been proposed to explain this association. These include overlapping pathophysiological mechanisms, an unhealthy lifestyle (poor dietary choices, smoking, lack of exercise), genetic factors and a lack of compliance with therapeutic programs. In addition to this, attention is increasing being focused on the metabolic side effects of (atypical) neuroleptics. Cases of acute ketoacidosis may also be associated with the use of these substances. Since none of the neuroleptics currently commercially available can be guaranteed to be free of metabolic side effects, strict monitoring of depressive or schizophrenic patients receiving such treatment is mandatory.
- 1 May 2005
- Published by Wolters Kluwer Health in Psychosomatic Medicine
- Vol. 67 (3) , 407-412
Visceral Fat Deposition and Insulin Sensitivity in Depressed Women With and Without Comorbid Borderline Personality Disorder
Major depressive disorder (MDD) is associated with increased intra-abdominal fat, an important antecedent of noninsulin-dependent diabetes mellitus (NIDDM) and cardiovascular disorders. Furthermore, MDD is commonly accompanied by endocrine and immune dysregulation that has also been discussed in connection with the pathogenesis of NIDDM and ischemic heart disease. In borderline personality disorder (BPD), a dysregulation of the hypothalamic–pituitary–adrenal system has also been described. Therefore, our study aimed at examining visceral fat, insulin resistance, and alterations of cortisol and cytokines in young depressed women with and without comorbid BPD. Visceral fat was measured in 18 premenopausal women with MDD and in 18 women comorbid with MDD and BPD by means of magnetic resonance tomography at the level of the first lumbar vertebral body. Twelve BPD patients without MDD and 20 healthy women served as the comparison groups. Concentrations of fasting cortisol, tumor necrosis factor-α, and interleukin-6 were measured, and indicators of insulin resistance and β-cell sensitivity were calculated according to the homeostasis assessment model. We found increased visceral fat in women comorbid with MDD and BPD, and to a lesser extent, in women with MDD but without BPD. Insulin sensitivity was reduced in comorbid patients. Serum interleukin-6 (IL-6) and tumor necrosis factor-α concentrations were significantly increased in both groups of depressed patients. Reduced insulin sensitivity correlated with the amount of visceral fat and with serum concentrations of IL-6. Young depressed women with and without comorbid BPD display increased visceral fat and may constitute a risk group for the development of NIDDM and the metabolic syndrome. Our data support the hypothesis that the immune and endocrine alterations associated with MDD and BPD may contribute to the pathophysiologic processes associated with NIDDM.
- 1 May 2005
- Published by Wolters Kluwer Health in Psychosomatic Medicine
- Vol. 67 (3) , 407-412
Visceral Fat Deposition and Insulin Sensitivity in Depressed Women With and Without Comorbid Borderline Personality Disorder
Major depressive disorder (MDD) is associated with increased intra-abdominal fat, an important antecedent of noninsulin-dependent diabetes mellitus (NIDDM) and cardiovascular disorders. Furthermore, MDD is commonly accompanied by endocrine and immune dysregulation that has also been discussed in connection with the pathogenesis of NIDDM and ischemic heart disease. In borderline personality disorder (BPD), a dysregulation of the hypothalamic–pituitary–adrenal system has also been described. Therefore, our study aimed at examining visceral fat, insulin resistance, and alterations of cortisol and cytokines in young depressed women with and without comorbid BPD. Visceral fat was measured in 18 premenopausal women with MDD and in 18 women comorbid with MDD and BPD by means of magnetic resonance tomography at the level of the first lumbar vertebral body. Twelve BPD patients without MDD and 20 healthy women served as the comparison groups. Concentrations of fasting cortisol, tumor necrosis factor-α, and interleukin-6 were measured, and indicators of insulin resistance and β-cell sensitivity were calculated according to the homeostasis assessment model. We found increased visceral fat in women comorbid with MDD and BPD, and to a lesser extent, in women with MDD but without BPD. Insulin sensitivity was reduced in comorbid patients. Serum interleukin-6 (IL-6) and tumor necrosis factor-α concentrations were significantly increased in both groups of depressed patients. Reduced insulin sensitivity correlated with the amount of visceral fat and with serum concentrations of IL-6. Young depressed women with and without comorbid BPD display increased visceral fat and may constitute a risk group for the development of NIDDM and the metabolic syndrome. Our data support the hypothesis that the immune and endocrine alterations associated with MDD and BPD may contribute to the pathophysiologic processes associated with NIDDM.
- 1 February 2005
- Published by Springer Nature in Der Nervenarzt
- Vol. 76 (2) , 205-208
Therapie der Clozapin-induzierten Hypersalivation mit Botulinum-Toxin B
- 1 February 2005
- Published by Springer Nature in Der Nervenarzt
- Vol. 76 (2) , 205-208
Therapie der Clozapin-induzierten Hypersalivation mit Botulinum-Toxin B
- 1 January 2005
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 162 (1) , 168-174
Bone Mineral Density, Markers of Bone Turnover, and Cytokines in Young Women With Borderline Personality Disorder With and Without Comorbid Major Depressive Disorder
The pathogenesis of bone loss in major depressive disorder is a matter of debate. Studies of bone loss in nonpsychiatric medical disorders have found an association between the activation of osteoclastic cells and an imbalance of pro- and antiinflammatory cytokines. Since major depressive disorder is also associated with alterations in serum cytokine concentrations, the authors hypothesized that bone loss in patients with major depressive disorder and comorbid borderline personality disorder may be associated with cytokines capable of activating osteoclastic cells. Twenty-two patients with borderline personality disorder and comorbid current or lifetime major depressive disorder were compared with 16 patients with borderline personality disorder who did not have major depressive disorder and 20 healthy volunteers. Bone mineral density was assessed by means of dual-energy x-ray absorptiometry. Markers of bone turnover as well as endocrine and immune measures were determined. The bone mineral density of 10 patients with borderline disorder plus current major depressive episode was significantly lower than that of the healthy subjects and the patients with borderline personality disorder without depression. Values of crosslaps, osteocalcin, serum cortisol, tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 were significantly higher in the patients with borderline disorder plus current major depressive episode than in the healthy subjects. Crosslaps correlated positively with TNF-alpha but negatively with bone mineral density at the lumbar spine. Patients with borderline personality disorder who did not have current or lifetime depression displayed no alterations of either bone mineral density or the immunological and hormonal measures examined. Young women with comorbid borderline personality disorder and major depressive disorder have an elevated risk for osteoporosis. Borderline personality disorder per se is not associated with low bone mineral density. These data suggest that the immune and endocrine disturbances associated with depressive disorders in the context of borderline personality disorder may play a role in the pathophysiological process underlying bone loss in the patients studied.
- 1 January 2005
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 162 (1) , 168-174
Bone Mineral Density, Markers of Bone Turnover, and Cytokines in Young Women With Borderline Personality Disorder With and Without Comorbid Major Depressive Disorder
The pathogenesis of bone loss in major depressive disorder is a matter of debate. Studies of bone loss in nonpsychiatric medical disorders have found an association between the activation of osteoclastic cells and an imbalance of pro- and antiinflammatory cytokines. Since major depressive disorder is also associated with alterations in serum cytokine concentrations, the authors hypothesized that bone loss in patients with major depressive disorder and comorbid borderline personality disorder may be associated with cytokines capable of activating osteoclastic cells. Twenty-two patients with borderline personality disorder and comorbid current or lifetime major depressive disorder were compared with 16 patients with borderline personality disorder who did not have major depressive disorder and 20 healthy volunteers. Bone mineral density was assessed by means of dual-energy x-ray absorptiometry. Markers of bone turnover as well as endocrine and immune measures were determined. The bone mineral density of 10 patients with borderline disorder plus current major depressive episode was significantly lower than that of the healthy subjects and the patients with borderline personality disorder without depression. Values of crosslaps, osteocalcin, serum cortisol, tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 were significantly higher in the patients with borderline disorder plus current major depressive episode than in the healthy subjects. Crosslaps correlated positively with TNF-alpha but negatively with bone mineral density at the lumbar spine. Patients with borderline personality disorder who did not have current or lifetime depression displayed no alterations of either bone mineral density or the immunological and hormonal measures examined. Young women with comorbid borderline personality disorder and major depressive disorder have an elevated risk for osteoporosis. Borderline personality disorder per se is not associated with low bone mineral density. These data suggest that the immune and endocrine disturbances associated with depressive disorders in the context of borderline personality disorder may play a role in the pathophysiological process underlying bone loss in the patients studied.
- 5 August 2004
- Published by Springer Nature in Osteoporosis International
- Vol. 16 (4) , 424-429
Decreased osteoprotegerin and increased bone turnover in young female patients with major depressive disorder and a lifetime history of anorexia nervosa
Low bone mineral density (BMD) is a frequent, often persistent complication in patients with major depressive disorder (MDD) and anorexia nervosa (AN) that increases the risk of pathologic fractures. The pathogenetic process underlying osteopenia in MDD and AN is still unclear, although several factors, including a dysbalance of cytokines, are associated with loss of bone mass. Alterations in the serum levels of cytokines have been observed in patients with MDD, AN, and other psychiatric disorders. Therefore, we examined serum levels of cytokines, markers of bone turnover, and BMD in 13 patients with MDD and a lifetime history of AN. Bone turnover markers (osteocalcin and C-terminal degradation products of type I collagen) and tumor necrosis factor α (TNF-α) in patients were significantly increased compared with those of the control group. Osteoprotegerin (OPG) in patients was significantly decreased. Eight of 13 patients (62%) displayed osteopenia at the lumbar spine. TNF-α correlated significantly with C-terminal degradation products of type I collagen, an osteoclastic marker, but significantly negatively with OPG. Our data suggest that TNF-α and OPG may play a role in the pathogenetic process underlying osteopenia in these patients.
- 5 August 2004
- Published by Springer Nature in Osteoporosis International
- Vol. 16 (4) , 424-429
Decreased osteoprotegerin and increased bone turnover in young female patients with major depressive disorder and a lifetime history of anorexia nervosa
Low bone mineral density (BMD) is a frequent, often persistent complication in patients with major depressive disorder (MDD) and anorexia nervosa (AN) that increases the risk of pathologic fractures. The pathogenetic process underlying osteopenia in MDD and AN is still unclear, although several factors, including a dysbalance of cytokines, are associated with loss of bone mass. Alterations in the serum levels of cytokines have been observed in patients with MDD, AN, and other psychiatric disorders. Therefore, we examined serum levels of cytokines, markers of bone turnover, and BMD in 13 patients with MDD and a lifetime history of AN. Bone turnover markers (osteocalcin and C-terminal degradation products of type I collagen) and tumor necrosis factor α (TNF-α) in patients were significantly increased compared with those of the control group. Osteoprotegerin (OPG) in patients was significantly decreased. Eight of 13 patients (62%) displayed osteopenia at the lumbar spine. TNF-α correlated significantly with C-terminal degradation products of type I collagen, an osteoclastic marker, but significantly negatively with OPG. Our data suggest that TNF-α and OPG may play a role in the pathogenetic process underlying osteopenia in these patients.